MAGEA3 and non-small cell lung carcinoma: Interestingly, adjuvant therapy with a MAGE-A3 CT antigen vaccine in patients with MAGE-A3-positive NSCLC has shown promising results [16], and allogeneic lymphocytes expressing recombinant T-cell receptors recognizing CT antigens NY-ESO-1 and MAGE-A3 were recently shown to effectively kill lung cancer cells [4].